Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...
Labiotech.eu

Can the thymus be drugged? TECregen raises $12 million to find out

Find out about TECregen's, a Basel-based company developing novel biologics designed to rejuvenate the thymus, “thymopoietics ...

Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic ...

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutationsKB407 transduction confirmed in all ...
Ventureburn

TECregen Seed Funding Drives $12.6 Million Push Into Thymus Regeneration

TECregen seed funding supports the development of thymus regeneration biologics designed to restore immune function and ...

SonoThera Launches $125M Series B at 44th J.P. Morgan Healthcare Conference to Advance Multiple Genetic Medicine Programs Toward First-in-Human Studies

SonoThera (TM), a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will officially launch a $125M ...
The Malaysian Reserve

TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman

Groundbreaking thymus-rejuvenating biologics are designed to restore immune function and promote lasting immune health throughout all stages of lifeBASEL, ...
The Pharma Letter

Investment to speed development of TECregen’s thymopoietic biologics

TECregen, a Swiss biotech advancing thymus regeneration, has announced the successful completion of a 10 million Swiss francs ...
The Pharma Letter

TECregen banks $12.5 million for thymus regeneration tech

Swiss biotech TECregen has raised 10 million Swiss francs ($12.6 million) in seed financing to advance its thymus ...
Targeted Oncology

FDA Fast-Tracks PARG Inhibitor for mBRCA Platinum-Resistant Ovarian Cancer

ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

As part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.S. and European markets ...

Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets - Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug ...

PM PT/4:30 PM ET FREMONT, CA / ACCESS Newswire / January 8, 2026 /Tivic Health® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that Management will host ...

TECregen AG: TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman

Groundbreaking thymus-rejuvenating biologics are designed to restore immune function and promote lasting immune health throughout all stages of lifeBASEL, Switzerland, Jan. 8, 2026 /PRNewswire/ ...